Search Results
Adam Brufsky, MD, PhD, discusses the issue of resistance to HER2-targeted therapy
Dr. Brufsky Discusses Resistance to HER2-Targeted Therapies
Dr. Brufsky on Challenges in Breast Cancer
Adam Brufsky, MD, PhD, describes the treatment landscape of HER2+ metastatic breast cancer
Adam Brufsky, MD, PhD, considers the investigation of poziotinib in HER2+ metastatic breast cancer
HER2-Targeted Therapy in Early Breast Cancer
An Overview of Immunotherapy in Breast Cancer - An Interview with Adam Brufsky
Dr. Brufsky on Implementing Pertuzumab in HER2+ Breast Cancer
Extended Adjuvant Therapy in HER2-Positive Disease
Adjuvant Therapy for ER+/HER2+ Breast Cancer
Identifying drivers of first-line HR+/HER2- metastatic breast cancer treatment choices
ESR Mutations and Resistance to Endocrine Therapy